MedPath

长春长庆药业集团有限公司

Ownership
-
Established
2004-08-02
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

136

NMPA:136

Drug Approvals

Citicoline Sodium Injection

Product Name
胞磷胆碱钠注射液
Approval Number
国药准字H22020423
Approval Date
Dec 18, 2023
NMPA

Reserpine Injection

Product Name
利血平注射液
Approval Number
国药准字H22020406
Approval Date
Dec 18, 2023
NMPA

Compound Ammonium Glycyrrhetate Injection

Product Name
复方甘草酸单铵注射液
Approval Number
国药准字H22026214
Approval Date
Dec 18, 2023
NMPA

Calcium Gluconate Injection

Product Name
葡萄糖酸钙注射液
Approval Number
国药准字H22020390
Approval Date
Dec 18, 2023
NMPA

Oxocamphor Injection

Product Name
氧化樟脑注射液
Approval Number
国药准字H22025735
Approval Date
Dec 18, 2023
NMPA

Ribavirin Injection

Product Name
利巴韦林注射液
Approval Number
国药准字H22020427
Approval Date
Dec 18, 2023
NMPA

Aminomethylbenzoic Acid Injection

Product Name
氨甲苯酸注射液
Approval Number
国药准字H22020404
Approval Date
Nov 27, 2023
NMPA

Procaine Hydrochloride Injection

Product Name
盐酸普鲁卡因注射液
Approval Number
国药准字H22020373
Approval Date
Nov 24, 2023
NMPA

Sodium Cromoglicate Eye Drops

Product Name
色甘酸钠滴眼液
Approval Number
国药准字H20074039
Approval Date
Jul 18, 2022
NMPA

Heparolysate Injection

Product Name
肝水解肽注射液
Approval Number
国药准字H20054214
Approval Date
Sep 28, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.